Tokyo Tape
Sign in
← Sakai Chemical Industry

Quarterly report · Q2

4078.TEDINET S100S5CT
Period2023-04-01 → 2023-09-30
Filed2023-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥40.5bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥83.9bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥42.7bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥917m2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥3.3bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥885m2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥4.6bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.8bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥773m2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥4.2bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)−¥2.0bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.9bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥3.0bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥131.6bnat 2023-09-30Cons.Assets
Total assets¥128.0bnat 2023-03-31Cons.Assets
Total assets¥128.4bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥50.9bnat 2023-09-30Cons.Liabilities
Total liabilities¥43.3bnat 2023-03-31Cons.Liabilities
Net assets / equity¥80.7bnat 2023-09-30Cons.Net assets
Net assets / equity¥84.7bnat 2023-03-31Cons.Net assets
Net assets / equity¥85.8bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥15.6bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥12.4bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥15.5bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥12.2bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥11.7bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥10.5bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥3.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥773m2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥2.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥1.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥3.3bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-125.532023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-153.572023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥144.852022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥177.482022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥68.082022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio60.5%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio62.9%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio63.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥635m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥635m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.1bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2023-04-01 → 2023-09-30¥36.8bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2023-04-01 → 2023-09-30¥36.3bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥498m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.9bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2023-04-01 → 2023-09-30¥4.3bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2023-04-01 → 2023-09-30¥4.2bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥136m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2023-04-01 → 2023-09-30¥144m
—segment totalrevenue2023-04-01 → 2023-09-30¥41.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥40.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥635m
—segment totalsegment profit2023-04-01 → 2023-09-30¥2.0bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥860m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥860m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥1.1bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2022-04-01 → 2022-09-30¥39.3bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2022-04-01 → 2022-09-30¥38.6bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥697m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2022-04-01 → 2022-09-30¥4.1bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥163m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2022-04-01 → 2022-09-30¥240m
—segment totalrevenue2022-04-01 → 2022-09-30¥43.6bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥42.7bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥860m
—segment totalsegment profit2022-04-01 → 2022-09-30¥4.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 522
ItemContextValueUnit
Net increase decrease in cash and cash equivalentsPrior1YTDDuration1118000000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration3336000000JPY
Cash and cash equivalentsPrior2YearInstant10549000000JPY
Cash and cash equivalentsPrior1YearInstant12188000000JPY
Cash and cash equivalentsPrior1QuarterInstant11667000000JPY
Cash and cash equivalentsCurrentQuarterInstant15524000000JPY
Haulage expenses sgaPrior1YTDDuration1073000000JPY
Haulage expenses sgaCurrentYTDDuration926000000JPY
Employees salaries and allowances sgaPrior1YTDDuration1904000000JPY
Employees salaries and allowances sgaCurrentYTDDuration1920000000JPY
Provision for bonuses sgaPrior1YTDDuration653000000JPY
Provision for bonuses sgaCurrentYTDDuration608000000JPY
Provision for directors bonuses sgaPrior1YTDDuration62000000JPY
Provision for directors bonuses sgaCurrentYTDDuration48000000JPY
Retirement benefit expenses sgaPrior1YTDDuration124000000JPY
Retirement benefit expenses sgaCurrentYTDDuration107000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E00780-000ChemicalReportableSegmentsMember38572000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E00780-000MedicineAndHealthCareReportableSegmentsMember4122000000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember42694000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration42694000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E00780-000ChemicalReportableSegmentsMember697000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E00780-000MedicineAndHealthCareReportableSegmentsMember163000000JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember860000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-860000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E00780-000ChemicalReportableSegmentsMember39269000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E00780-000MedicineAndHealthCareReportableSegmentsMember4285000000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember43555000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-860000000JPY
Net salesPrior1YTDDuration42694000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E00780-000ChemicalReportableSegmentsMember4163000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E00780-000MedicineAndHealthCareReportableSegmentsMember240000000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember4403000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-1136000000JPY
Operating incomePrior1YTDDuration3267000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E00780-000ChemicalReportableSegmentsMember36313000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E00780-000MedicineAndHealthCareReportableSegmentsMember4158000000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember40471000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration40471000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E00780-000ChemicalReportableSegmentsMember498000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E00780-000MedicineAndHealthCareReportableSegmentsMember136000000JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember635000000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-635000000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E00780-000ChemicalReportableSegmentsMember36812000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E00780-000MedicineAndHealthCareReportableSegmentsMember4295000000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember41107000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-635000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass